Skip to Main Content

GB001 in Adult Subjects With Moderate to Severe Asthma

Conditions

Asthma

Phase II

What is the purpose of this trial?

A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe asthma and an eosinophilic phenotype with respect to asthma worsening at the end of 24 weeks of treatment.

  • Trial with
    Gossamer Bio, Inc.
  • Start Date
    07/21/2019
  • End Date
    06/29/2020
Trial Image

For more information about this study, contact:

Terri-Dawn Levesh

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/05/2019
  • Study HIC
    #2000024277